Infants and young children generate more durable antibody responses to SARS-CoV-2 infection than adults.
Clinical finding
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
20 Oct 2023
20 Oct 2023
Historique:
received:
28
07
2023
revised:
25
08
2023
accepted:
15
09
2023
medline:
12
10
2023
pubmed:
12
10
2023
entrez:
12
10
2023
Statut:
epublish
Résumé
As SARS-CoV-2 becomes endemic, it is critical to understand immunity following early-life infection. We evaluated humoral responses to SARS-CoV-2 in 23 infants/young children. Antibody responses to SARS-CoV-2 spike antigens peaked approximately 30 days after infection and were maintained up to 500 days with little apparent decay. While the magnitude of humoral responses was similar to an adult cohort recovered from mild/moderate COVID-19, both binding and neutralization titers to WT SARS-CoV-2 were more durable in infants/young children, with spike and RBD IgG antibody half-life nearly 4X as long as in adults. IgG subtype analysis revealed that while IgG1 formed the majority of the response in both groups, IgG3 was more common in adults and IgG2 in infants/young children. These findings raise important questions regarding differential regulation of humoral immunity in infants/young children and adults and could have broad implications for the timing of vaccination and booster strategies in this age group.
Identifiants
pubmed: 37822504
doi: 10.1016/j.isci.2023.107967
pii: S2589-0042(23)02044-8
pmc: PMC10562792
doi:
Types de publication
Journal Article
Langues
eng
Pagination
107967Subventions
Organisme : NIAID NIH HHS
ID : U01 AI144673
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI057266
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA260563
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
M.S.S. has served as an advisor for Ocugen and Moderna. E.J.A. has consulted for Pfizer, Sanofi Pasteur, Janssen, and Medscape, and his institution receives funds to conduct clinical research unrelated to this manuscript from MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Sonfi-Pasteur, Janssen, and Micron. He also serves on data and safety monitoring boards for Kentucky BioProcessing, Inc., and Sanofi Pasteur. His institution has also received funding from NIH to conduct clinical trials of Moderna and Janssen COVID-19 vaccines. M.A.S. received funding from CDC, Pfizer, Merck, and Cepheid to study immune response to respiratory virus infections and vaccinations.
Références
Curr Protoc Immunol. 2020 Dec;131(1):e116
pubmed: 33215858
N Engl J Med. 2023 Jan 12;388(2):183-185
pubmed: 36546661
N Engl J Med. 2021 Aug 12;385(7):664-666
pubmed: 34233096
J Infect Dis. 2022 Apr 1;225(7):1129-1140
pubmed: 34888688
Sci Rep. 2021 Mar 10;11(1):5538
pubmed: 33692390
Front Immunol. 2022 Nov 17;13:1031924
pubmed: 36466865
Nat Rev Microbiol. 2023 Mar;21(3):162-177
pubmed: 36653446
Cell Rep Med. 2020 Jun 23;1(3):100040
pubmed: 32835303
Biol Sex Differ. 2020 Sep 18;11(1):53
pubmed: 32948238
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32826322
PLoS Negl Trop Dis. 2018 Oct 24;12(10):e0006862
pubmed: 30356267
Lancet. 2022 Jul 23;400(10348):269-271
pubmed: 35809579
J Genet Genomics. 2021 Feb 20;48(2):107-114
pubmed: 34006471
Sci Adv. 2022 Oct 7;8(40):eadd2032
pubmed: 36197988
JAMA. 2022 Mar 15;327(11):1085-1087
pubmed: 35113143
Emerg Microbes Infect. 2021 Dec;10(1):664-676
pubmed: 33734013
Immunotargets Ther. 2020 Sep 29;9:143-149
pubmed: 33062618
Cell Rep Med. 2021 Apr 20;2(4):100228
pubmed: 33748788
Cell Rep Med. 2021 Jul 20;2(7):100354
pubmed: 34250512
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Nature. 2021 Feb;590(7844):140-145
pubmed: 33137809
Cell Mol Immunol. 2021 Jul;18(7):1826-1828
pubmed: 34059791
Proc Biol Sci. 2015 Dec 22;282(1821):20143085
pubmed: 26702035
Nat Commun. 2022 Jan 10;13(1):128
pubmed: 35013206
EBioMedicine. 2021 Sep;71:103561
pubmed: 34455390
J Infect. 2021 Aug;83(2):237-279
pubmed: 34052240
Cell Rep Med. 2021 Jul 20;2(7):100327
pubmed: 34124701
Nat Rev Immunol. 2021 Jun;21(6):395-404
pubmed: 33927374
Cell Host Microbe. 2021 Apr 14;29(4):516-521.e3
pubmed: 33798491
J Womens Health (Larchmt). 2021 May;30(5):646-653
pubmed: 33826864
Nat Commun. 2022 Feb 9;13(1):852
pubmed: 35140233
Cell Host Microbe. 2020 May 13;27(5):841-848.e3
pubmed: 32289263
Ann Intern Med. 2021 Jun;174(6):811-821
pubmed: 33721517
Cell. 2020 Jun 25;181(7):1458-1463
pubmed: 32492407
Nat Rev Immunol. 2020 Jul;20(7):442-447
pubmed: 32528136
J Infect. 2023 Jan;86(1):e10-e12
pubmed: 36067868
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
Cell Rep. 2021 Feb 16;34(7):108737
pubmed: 33545052
Cell Rep Med. 2021 Jul 20;2(7):100329
pubmed: 34151306
Arch Dis Child Fetal Neonatal Ed. 2021 May;106(3):330-335
pubmed: 32943533
J Virol. 2022 Sep 14;96(17):e0058222
pubmed: 35976000
JAMA Netw Open. 2022 Sep 1;5(9):e2231778
pubmed: 36107426
Proc Natl Acad Sci U S A. 2022 Aug 2;119(31):e2204336119
pubmed: 35858382
Cell. 2021 Apr 1;184(7):1858-1864.e10
pubmed: 33631096
J Med Virol. 2023 Jan;95(1):e28138
pubmed: 36097349
Science. 2021 Mar 25;:
pubmed: 33766944
Nat Commun. 2021 Feb 19;12(1):1162
pubmed: 33608522
Nat Rev Immunol. 2018 Jan;18(1):46-61
pubmed: 29063907
Cell Rep Med. 2022 Mar 29;3(4):100603
pubmed: 35480625
JAMA Netw Open. 2022 Jul 1;5(7):e2221616
pubmed: 35816313
Med. 2022 Jan 14;3(1):25-27
pubmed: 35590141
Annu Rev Med. 2022 Jan 27;73:17-39
pubmed: 34669432